Zealand Pharma AS Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Zealand Pharma AS Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 25 Jul 2018 | Lorem |
| Sanofi’s LixiLan as a second-line T2D treatment to be stymied by patient preference for oral options – experts | 13 Nov 2014 | Sony Salzman, Jinan Harb |
| Sanofi’s Lixilan should yield positive efficacy and safety in two Phase III diabetes trials – experts | 05 Nov 2014 | Sony Salzman, Jinan Harb |
| Novo's IDegLira to have superior diabetes efficacy offset by price premium over Sanofi’s LixiLan – experts | 18 Jul 2014 | Sony Salzman, Jinan Harb |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer